

Title (en)

COMPOSITIONS AND TREATMENTS USING EX VIVO ACTIVATED CELLS FOR MYELOSUPPRESSED PATIENTS

Title (de)

ZUSAMMENSETZUNGEN UND BEHANDLUNGEN FÜR MYELOSUPPRESSIONSPATIENTEN UNTER VERWENDUNG VON EX-VIVO-AKTIVIERTEN ZELLEN

Title (fr)

COMPOSITIONS ET TRAITEMENTS UTILISANT DES CELLULES ACTIVEES EX VIVO POUR PATIENTS PRESENTANT UNE MYELOSUPPRESSION

Publication

EP 1789089 A2 20070530 (EN)

Application

EP 05802443 A 20050805

Priority

- US 2005027949 W 20050805
- US 93916804 A 20040910
- US 93930204 A 20040910

Abstract (en)

[origin: WO2006031312A2] The disclosure includes protocols for activating and administering human blood cells to cancer patients, severely myelosuppressed patients, including severely myelosuppressed patients treated for cancer, e.g., by chemotherapy or radiation. The protocol may include culturing blood cells in the presence of activating agents, for example, a cytokine and an ionophore.

IPC 8 full level

A61K 35/14 (2006.01); **A61K 35/15** (2015.01); **C07K 14/475** (2006.01); **C07K 14/52** (2006.01); **C07K 14/55** (2006.01); **C12N 5/06** (2006.01)

CPC (source: EP)

A61K 39/461 (2023.05); **A61K 39/464** (2023.05); **A61K 45/06** (2013.01); **A61P 7/00** (2017.12); **A61P 7/06** (2017.12); **A61P 43/00** (2017.12); **A61K 2239/26** (2023.05); **A61K 2239/31** (2023.05); **A61K 2239/38** (2023.05)

Designated contracting state (EPC)

DE ES FR GB

Designated extension state (EPC)

AL BA HR MK YU

DOCDB simple family (publication)

WO 2006031312 A2 20060323; **WO 2006031312 A3 20070510**; EP 1789089 A2 20070530; EP 1789089 A4 20090826; JP 2008512454 A 20080424

DOCDB simple family (application)

US 2005027949 W 20050805; EP 05802443 A 20050805; JP 2007531171 A 20050805